Articles related to ALERTS/WARNINGS/ADVISEMENT

Stay abreast of the latest developments in patient care. Learn more about the FDA’s recent warning on the potential risks associated with compounded ketamine products used for treating psychiatric disorders.

FDA Cautions Against Hidden Drug Ingredients in Joint Pain Supplements In response to recent findings, the FDA warns of significant health risks associated with three specific dietary supplements marketed for joint pain and rheumatoid arthritis relief due to the discovery of unlisted active pharmaceutical ingredients.

Understanding Xylazine: The Rising Challenge in Opioid Crisis Management As physicians, it’s crucial to stay informed about emerging drug threats. Xylazine, a powerful livestock tranquilizer mixed into fentanyl, is one such threat that’s gaining momentum.

The case involves a 73-year-old patient, Ms. B, who had a history of rheumatoid arthritis and was taking prednisone for adrenal insufficiency caused by a pituitary tumor. She was treated by an internist, Dr. R, for various ailments over a period of four years. In November 2016, Ms. B was diagnosed with severe community-acquired pneumonia and admitted to the hospital, where she was treated with levofloxacin. After being discharged, she continued taking levofloxacin and suffered an acute rupture of the gluteus medius tendon, resulting in significant disabilities. Ms. B filed a lawsuit against Dr. R, alleging negligence and failure to inform her about the risks and contraindications of the medication. Dr. R sought a summary judgment to have the case dismissed but was denied by the court. The court ruled that a Boxed Warning on a medication, such as the one associated with levofloxacin, can create a triable issue of fact regarding a physician’s departure from accepted medical practice. Dr. R claimed he was unaware of the risks and relied on the hospitalists’ choice of medication, but the court found that he should have been knowledgeable about the specific risks and suitability of the medication for his patient. The case […]

To reduce overuse of vitamin D across 11 hospitals and 70 clinics, a best practice advisory was created to be triggered when a clinician placed an order for 25-hydroxyvitamin D 25(OH)D level testing sooner than three months after a previous test. The advisory reduced testing by 44–46% across 11 hospitals and 70 ambulatory centers.

A federal science panel has recommended revisions to a National Toxicology Program (NTP) report on the potential associations between fluoride and IQ. The NTP Board of Scientific Counselors unanimously voted to adopt the findings and recommendations of a working group that assessed the report. The systematic literature review, which has been ongoing for several years, aims to summarize the existing research on the relationship between fluoride exposure and neurodevelopmental and cognitive health. The panel identified potential biases in the study and suggested revisions to the meta-analysis based on reviewer comments. The American Dental Association (ADA) expressed concerns about the report’s methodology and transparency, urging the NTP not to publish it until the concerns are addressed. The draft report claims that higher fluoride exposure is associated with lower IQ in children, but several studies published after the study period ended in 2020 have questioned the methodology used and the strength of the conclusions. The BSC Working Group recommended that the NTP acknowledge potential publication bias and make improvements to the clarity and language used in the report. The recommendations will be forwarded to the NTP director for further consideration.